logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 16 of 16 Items
Showing 1 - 16 of 16 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (16)
  • CSV
  • BibTeX
  • EndNote
  • All Results (16)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Commentary
Journal Article
|
Commentary

The 1/4/6x24 campaign to cure tuberculosis quickly

McKenna L, Frick M, Angami K, Dubula V, Furin J,  et al.
Journal Article
|
Research

Diagnostics to support the scaling up of shorter, safer tuberculosis regimens

Branigan D, Denkinger CM, Furin J, Heitkamp P, Deborggraeve S,  et al.
2023-07-31 • Lancet Microbe
2023-07-31 • Lancet Microbe

Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa

Sinanovic E, Ramma L, Vassall A, Azevedo VD, Wilkinson LS,  et al.
2015-02-01 • International Journal of Tuberculosis and Lung Disease
2015-02-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa.

OBJECTIVE
To estimate and compare the c...

Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A,  et al.
2020-03-20 • European Respiratory Journal
2020-03-20 • European Respiratory Journal
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS,  et al.
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F,  et al.
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF,  et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G,  et al.
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N,  et al.
2015-07-19 • International Journal of Tuberculosis and Lung Disease
2015-07-19 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.

OBJECTIVE
To descri...

MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM,  et al.
2020-02-01 • International Journal of Infectious Diseases
2020-02-01 • International Journal of Infectious Diseases
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at provid...

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Schnippel K, Ndjeka N, Maartens G, Meintjes GA, Master I,  et al.
2018-09-01 • Lancet Respiratory Medicine
2018-09-01 • Lancet Respiratory Medicine
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?

Ndjeka N, Conradie F, Meintjes GA, Reuter A, Hughes J,  et al.
2020-07-23 • European Respiratory Journal
2020-07-23 • European Respiratory Journal
Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...

Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

Conradie F, Meintjes GA, Hughes J, Maartens G, Ferreira H,  et al.
2014-03-01 • South African Medical Journal
2014-03-01 • South African Medical Journal
While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a...
2023-01-01 • Nature Medicine
2023-01-01 • Nature Medicine

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

Guglielmetti L, Hewison CCH, Avaliani Z, Hughes AJ, Kiria N,  et al.
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...